Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen, Transkaryotic, sanofi-aventis renal, gene/cell therapy news

The U.K.'s House of Lords upheld a 2002 decision from the Court of Appeal that Dynepo epoetin delta from TKTX and Aventis, now SAN, did not infringe

Read the full 277 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE